Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02900716
Title Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Zhejiang DTRM Biopharma
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

chronic lymphocytic leukemia

marginal zone B-cell lymphoma

mantle cell lymphoma

follicular lymphoma

Therapies

DTRMWXHS-12 + Everolimus + Pomalidomide

DTRMWXHS-12

DTRMWXHS-12 + Everolimus

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.